Quadratus Lumborum Block Versus Transversus Abdominus Plane Block for Pain Management After Donor Nephrectomy

Kidney Donor Clinical Trial

Official title:

Quadratus Lumborum Block Versus Transversus Abdominus Plane Block for Pain Management After Donor Nephrectomy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03476850
• Other study ID #: Pro00073925
• Status: Completed
• Phase: N/A
• Start date: February 19, 2018
• Est. completion date: May 22, 2019

Study information

• Verified date: June 2020
• Source: Medical University of South Carolina
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate quadratus lumborum block effect on post operative pain scores during the first 24 hours after surgery as compared to transversus abdominis plane block after laparoscopic donor nephrectomy patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: May 22, 2019
• Est. primary completion date: May 22, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients undergoing laparoscopic assisted donor nephrectomy

• Patients that have elected to have a nerve block

• 18 years of age or older

• Patients of ASA status I - III

Exclusion Criteria:

• Chronic pain or narcotic usage during the preceding 30 days

• Infection at or near the intended needle insertion site

• Complex or altered abdominal wall anatomy

• Weight <45kg

Related Conditions & MeSH terms

• Kidney Donor

Intervention

Procedure:
• QL Block
Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance QL blocks. QL block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
• TAP Block
Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance TAP blocks. TAP block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.

Locations

Country	Name	City	State
United States	Medical University of South Carolina	Charleston	South Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of South Carolina

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Average Pain Score	NRS patient reported (number rated pain score, 0=no pain - 10=highest pain) over the first 24 hours post operative.	24 hours post operative
Secondary	Total Cumulative Opioids	opiate consumption first 72 hours post operatively	72 hours
Secondary	Number of Participants With Nausea or Emesis Requiring Antiemetic Medication	Antiemetics given in PACU. Occurrence of nausea or emesis requiring antiemetic medication administration in PACU.	24 hours
Secondary	Number of Participants With Block Related Complications		24 hours
Secondary	Length of Stay in Post Anesthesia Care Unit (PACU)	Duration of PACU stay.	24 hours
Secondary	Length of Hospital Stay	The time from surgery completion to subject meeting discharge criterion.	3 days